Acta Ortopédica Brasileira (Aug 2019)

BRAZILIAN CONSENSUS STATEMENT ON VISCOSUPPLEMENTATION OF THE KNEE (COBRAVI)

  • Gustavo Constantino de Campos,
  • Eduardo Branco de Sousa,
  • Paulo César Hamdan,
  • Cyro Scala de Almeida Júnior,
  • Antonio Martins Tieppo,
  • Marcia Uchôa de Rezende,
  • Adrieni Antunes do Amaral Alchaar,
  • Carlos Bruno Pinheiro,
  • Eduardo de Melo Carvalho Rocha,
  • Fabiano Gonçalves Cunha,
  • Ivan Pacheco,
  • Mário Sérgio Rossi Vieira,
  • Sílvio Figueira Antonio,
  • Zartur José Barcelos Menegassi

DOI
https://doi.org/10.1590/1413-785220192704218616
Journal volume & issue
Vol. 27, no. 4
pp. 230 – 236

Abstract

Read online Read online

ABSTRACT Objective: The aim of this consensus statement on viscosupplementation is to serve as a reference document based on relevant literature and clinical experience in the treatment of knee osteoarthritis using an intra-articular injection of hyaluronic acid, covering key aspects such as clinical indications, effectiveness, and tolerability. Methods: A multidisciplinary panel including two sports medicine physicians, six orthopedists, four physiatrists, and two rheumatologists were selected based on their clinical and academic experience of viscosupplementation. Sixteen statements were prepared and discussed, after which a vote was held. Each member of the panel gave a score between 0 and 10 on a Likert scale, specifying their level of agreement with the statement. Results: The panel reached a consensus on several issues. Specifically, the panel agreed that the best indication is for mild to moderate knee arthrosis; prior or concomitant use of intraarticular triamcinolone hexacetonide may optimize the effect of hyaluronic acid; viscosupplementation should not be performed as an isolated procedure but in conjunction with other rehabilitative and pharmacological measures; viscosupplementation has analgesic, anti-inflammatory, and chondroprotective effects; and viscosupplementation is cost-effective. Conclusion: This consensus statement provides clear information and guidance for both individuals and payers. Level of evidence V, Consensus statement.

Keywords